Terms: = Bone cancer AND PAM50 AND Treatment
4 results:
1. Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer.
Dieci MV; Conte P; Bisagni G; Bartolini S; Frassoldati A; Generali D; Piacentini F; Griguolo G; Tagliafico E; Brasó Maristany F; Chic N; Paré L; Miglietta F; Vicini R; D'Amico R; Balduzzi S; Prat A; Guarneri V
J Natl Cancer Inst; 2024 Jan; 116(1):69-80. PubMed ID: 37676829
[TBL] [Abstract] [Full Text] [Related]
2. Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies.
Prat A; Chaudhury A; Solovieff N; Paré L; Martinez D; Chic N; Martínez-Sáez O; Brasó-Maristany F; Lteif A; Taran T; Babbar N; Su F
J Clin Oncol; 2021 May; 39(13):1458-1467. PubMed ID: 33769862
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast cancer Treated With Letrozole With or Without Lapatinib.
Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
[TBL] [Abstract] [Full Text] [Related]
4. Clinical utility of genetic signatures in selecting adjuvant treatment: Risk stratification for early vs. late recurrences.
Hayes DF
Breast; 2015 Nov; 24 Suppl 2():S6-S10. PubMed ID: 26238437
[TBL] [Abstract] [Full Text] [Related]
